Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Director departure
Appointed director
|
|
AVENUE THERAPEUTICS, INC. (ATXI)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/10/2023 |
8-K
| Quarterly results |
| 05/12/2023 |
8-K
| Quarterly results|
Docs:
|
"Avenue Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights Miami, FL – May 12, 2023 – Avenue Therapeutics, Inc. , a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2023. “Avenue is progressing its neuro-focused clinical stage pipeline and 2023 is off to a strong start with AJ201, a first in class small molecule for the treatment of Spinal and Bulbar Muscular Atrophy , now in an ongoing Phase 1b/2a clinical trial, and BAER-101, a potentially more tolerable drug for the treatment of epilepsy and acute anxiety, advancing toward Phase 1b studies in each indication. We..." |
|
| 11/10/2022 |
8-K
| Quarterly results |
| 08/14/2020 |
8-K
| Quarterly results |
| 05/11/2020 |
8-K
| Quarterly results |
| 11/04/2019 |
8-K
| Quarterly results |
| 08/14/2019 |
8-K
| Quarterly results |
| 05/13/2019 |
8-K
| Quarterly results |
| 11/14/2018 |
8-K
| Quarterly results|
Docs:
|
"Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights – November 14, 2018 – Avenue Therapeutics, Inc. , a specialty pharmaceutical company focused on the development and commercialization of intravenous tramadol, today reported financial results and recent corporate highlights for the third quarter ended September 30, 2018. Lucy Lu, M.D., Avenue’ s President and Chief Executive Officer, said, “Yesterday, we were very pleased to announce definitive agreements with InvaGen Pharmaceuticals, Inc., USA , a subsidiary of Cipla Limited, a leading pharmaceutical company, with two closing stages, subject to shareholder approval and certain closing conditions. At the first stage closing, InvaGen will acquire, through the issuance by Avenue of new shares, sh..." |
|
| 05/03/2018 |
8-K
| Quarterly results |
|
|